Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027066 (
myoclonus
)
4,275
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The high pressure neurological syndrome (HPNS) occurs when man or animals are exposed to hyperbaric pressure. Four non-competitive N-methyl-D-aspartate (NMDA) antagonists - MK-801, phencyclidine (PCP), SKF 10,047 and ketamine were tested in rats for effects on the HPNS. All drugs were injected i.p. prior to compression; ketamine was also infused i.v. Control rats received saline. Rats were exposed individually to increasing helium pressure (PO2 0.5 atmospheres absolute ATA). Three endpoints were used to assess HPNS: onset pressures for tremor,
myoclonus
and convulsions. Neither MK-801 (0.03 and 0.3 mg/kg) nor SKF 10,047 (50 mg/kg) had any effect on the onset pressures for tremor,
myoclonus
or convulsions, although the type of seizure was modified from the clonic/tonic seizure seen in controls to purely clonic. PCP (5 mg/kg) had no effect on the endpoints, but pressure enhanced the excitation and stereotypy seen at 1 ATA.
Ketamine
(100 mg/kg i.p.) did not affect tremor or
myoclonus
; ketamine infused i.v. at pressure only prevented tremor and
myoclonus
at 'anaesthetizing' concentrations. Our results show that these non-competitive NMDA antagonists had little effect on HPNS, in contrast to competitive NMDA antagonists, such as AP7, which are highly effective. Possible explanations for this lack of effect include (1) interactions with NMDA receptor channels are pressure dependent; (2) other actions of these antagonists override their effects on the NMDA receptor channel.
...
PMID:The effects of non-competitive NMDA receptor antagonists on rats exposed to hyperbaric pressure. 254 78
Morphine administration can lead to a variety of side-effects, including
myoclonus
. In an animal model, high morphine doses given intrathecally elicit hindlimb myoclonic seizures which are not influenced by traditional opioid receptor antagonists, such as naloxone.
Ketamine
prevents this seizure-like activity in a dose-dependent manner. The response is stereoselective, with S-ketamine far more potent than R-ketamine. A competitive NMDA antagonist, NPC17742, also prevents the seizures, although less potently than ketamine. Dextromethorphan has limited activity in this model, while haloperidol and pentothal are without any effect.
...
PMID:Blockade of morphine-induced hindlimb myoclonic seizures in mice by ketamine. 907 78
Methadone is generally believed to be devoid of neuroexcitatory properties, and its use is increasing. This paper reports two cases of
myoclonus
with high-dose parenteral methadone in patients with cancer under hospice care. This side effect may be dose related and/or due to the parenteral route of administration. Reduction of the dose and change of route was sufficient to eliminate the
myoclonus
while maintaining an adequate pain control. Possible mechanisms for methadone causing
myoclonus
include a redistribution of receptor saturation in the N-methyl-D-aspartate (NMDA) and delta receptors.
Ketamine
may be an option for patients with intractable pain who develop methadone-induced
myoclonus
.
...
PMID:Myoclonus associated with high-dose parenteral methadone. 1871 74